Origanum

by | Mar 21, 2018 | Origanum

How Can We Help?
You are here:
< Back

AMB-CHMINACA or MMB-CHMINACA (also known as MA-CHMINACA) is an indazole-based synthetic cannabinoid[1] that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.[2][3][4]

Legal status

AMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[5]

Sweden's public health agency classified AMB-CHMINACA as a narcotic substance, on January 18, 2019.[6]

See also

References

  1. ^ Akamatsu S, Yoshida M (January 2016). "Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray". Journal of Mass Spectrometry. 51 (1): 28–32. Bibcode:2016JMSp...51...28A. doi:10.1002/jms.3722. PMID 26757069.
  2. ^ "MA-CHMINACA". Cayman Chemical. Retrieved 21 July 2015.
  3. ^ "MA-CHMINACA". Southern Association of Forensic Scientists. Archived from the original on 27 September 2015. Retrieved 21 July 2015.
  4. ^ Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
  5. ^ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 21 July 2015.
  6. ^ "Sexton nya ämnen klassas som narkotika eller hälsofarlig vara" [Sixteen new substances classified as narcotics or dangerous to health] (in Swedish). Folkhälsomyndigheten. 18 January 2019. Archived from the original on 3 June 2021. Retrieved 11 November 2019.


Categories
Table of Contents